BIOMAT Database Logo BIOMAT Database Logo

Low-dose CU 32-085 (mesulergine) in previously untreated Parkinson's disease. 1984

A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
January 1986, Clinical neuropharmacology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Mesulergine and pergolide in previously untreated Parkinson's disease.
April 1987, Journal of neurology, neurosurgery, and psychiatry,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Dopaminergic properties of mesulergine (CU 32-085) and its metabolites.
January 1984, Journal of neural transmission,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Mesulergine (CU32-085) in the treatment of Parkinson's disease.
April 1985, Annals of neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
January 1985, Journal of neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
April 1983, Neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085.
January 1983, Advances in neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
January 1983, Journal of neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
January 1982, Journal of neurology,
A M Bonnet, and M Esteguy, and J Guimaraes, and F Lhermitte, and Y Agid
Puerperal lactation inhibition with a novel 8 alpha-aminoergoline (CU 32-085).
January 1984, Gynecologic and obstetric investigation,
Copied contents to your clipboard!